SARS-CoV-2 Enzymes: from Virus-Host Interactions to Identification of Innovative Therapeutic Approaches
A special issue of Catalysts (ISSN 2073-4344). This special issue belongs to the section "Biocatalysis".
Deadline for manuscript submissions: closed (20 February 2022) | Viewed by 8678
Special Issue Editors
Interests: small biomolecules; molecular modeling; enzyme as a catalyst; combination therapy; inhibitors or decoy acceptors as drugs; carbohydrates
Special Issues, Collections and Topics in MDPI journals
Interests: biomolecular structure; X-ray protein crystallography; cell division regulation; cell signalling; macromolecular complexes; early stage drug discovery; chemoinformatics
Special Issue Information
Dear Colleagues,
The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 constitutes the greatest public health concern of our time. A total of 29 proteins are predicted to be encoded by the SARS-CoV-2 genome. The function(s) of some of these proteins remain(s) obscure, whereas others have been established. Some of these proteins have been identified as promising targets for new small-size drugs, biological such as therapeutic antibodies and siRNA-based approaches as well as vaccine development to treat COVID-19. Undoubtedly, an enhanced understanding of the activity and potential druggability of the pool of SARS-CoV-2 enzymes is of paramount importance to ensure progress in these areas. A steady stream of recent primary research publications and review articles are testimony to the multiple efforts across the globe to tackle COVID-19. However, a more holistic account of SARS-CoV-2 enzyme function, mode of regulation, and exploitation as suitable drug targets remain an important pending assignment in the field. This research topic addresses this gap in knowledge and aims to include contributions from leading scientists with a long-standing interest in coronavirus biology, ranging from phylogenetics analysis and the study of coronavirus–host interactions, to the effect of SARS-CoV-2 enzymes in the immune response, to the discovery of specific inhibitors to suppress their biological activity.
Dr. Agatha Bastida Codina
Dr. Victor M Bolanos-Garcia
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Catalysts is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SARS-CoV-2
- coronavirus
- COVID-19
- antivirals
- vaccine
- antibody
- docking
- enzyme inhibitor
- molecular modeling
- protein–protein interaction
- structural genomics
- interactome
- virtual screening
- nonstructural proteins
- spike protein
- virus–host interaction
